The aim of this study was to demonstrate the clinicopathological features, prognostic outcomes and fibroblast growth factor receptor 3 (FGFR3) protein expression status of a large series (n = 45) of urothelial carcinoma of bladder patients aged 30 or younger, retrospectively. We identified an age gradient (an age of 25, 26 and 27 years), classified patients as ≤25 or >25, ≤26 or >26, ≤27 or >27 years, respectively, and compared variables including recurrence events and FGFR3 expression patterns between different groups. Patients aged 25 years or younger were less likely to experience tumor recurrence (p = 0.046), were more likely to develop smaller size tumors (p = 0.040) and expressed more proportion of negative pattern of FGFR3 protein (p = 0.036). Patients aged 25 years or younger were less likely to develop tumor recurrence and revealed more proportion of negative pattern of FGFR3 expression than those aged 26–30 years did. We identified patients aged 25 years or younger as the true “young” urothelial carcinoma patients, carrying distinct clinical outcomes and molecular tumorigenesis.
Urothelial carcinoma Bladder Young FGFR3
This is a preview of subscription content, log in to check access.
Conflict of interest
Haichao Huang, Mengkui Sun, Jie Jin and Xin Li declare no conflict of interest.
Williamson SR, Lopez-Beltran A, MacLennan GT, et al. Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults. Urol Oncol. 2013;31:414–26.CrossRefPubMedGoogle Scholar
Hoenig DM, McRae S, Chen SC, et al. Transitional cell carcinoma of the bladder in the pediatric patient. J Urol. 1996;156:203–5.CrossRefPubMedGoogle Scholar
Bujons A, Caffaratti J, Garat JM, et al. Long-term follow-up of transitional cell carcinoma of the bladder in childhood. J Pediatr Urol. 2014;10:167–70.CrossRefPubMedGoogle Scholar
Yossepowitch O, Dalbagni G. Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome. J Urol. 2002;168:61–6.CrossRefPubMedGoogle Scholar
Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003;63:8108–12.PubMedGoogle Scholar
van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004;64:1911–4.CrossRefPubMedGoogle Scholar
Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213:91–8.CrossRefPubMedCentralPubMedGoogle Scholar
Williamson SR, Wang M, Montironi R, Eble JN, Lopez-Beltran A, Zhang S, et al. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. Mod Pathol. 2014;27:1540–8.CrossRefPubMedGoogle Scholar
Wild PJ, Giedl J, Stoehr R, Junker K, Boehm S, van Oers JM, et al. Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. J Pathol. 2007;211:18–25.CrossRefPubMedGoogle Scholar
Maeng YH, Eun SY, Huh JS. Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder. Korean J Urol. 2010;51:94–100.CrossRefPubMedCentralPubMedGoogle Scholar
Javadpour N, Mostofi FK. Primary epithelial tumors of the bladder in the first two decades of life. J Urol. 1969;101:706–10.PubMedGoogle Scholar
Lerena J, Krauel L, Garcia-Aparicio L, Vallasciani S, Sunol M, Rodo J. Transitional cell carcinoma of the bladder in children and adolescents: six-case series and review of the literature. J Pediatr Urol. 2010;6:481–5.CrossRefPubMedGoogle Scholar
Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein JI. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification. J Urol. 2005;174:1976–80.CrossRefPubMedGoogle Scholar
Patel R, Tery T, Ninan GK. Transitional cell carcinoma of the bladder in first decade of life. Pediatr Surg Int. 2008;24:1265–8.CrossRefPubMedGoogle Scholar
Migaldi M, Rossi G, Maiorana A, Sartori G, Ferrari P, De Gaetani C, et al. Superficial papillary urothelial carcinomas in young and elderly patients: a comparative study. BJU Int. 2004;94:311–6.CrossRefPubMedGoogle Scholar
Telli O, Sarici H, Ozgur BC, Doluoglu OG, Sunay MM, Bozkurt S, et al. Urothelial cancer of bladder in young versus older adults: clinical and pathological characteristics and outcomes. Kaohsiung J Med Sci. 2014;30:466–70.CrossRefPubMedGoogle Scholar
Stanton ML, Xiao L, Czerniak BA, Guo CC. Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59 cases. Arch Pathol Lab Med. 2013;137:1337–41.CrossRefPubMedCentralPubMedGoogle Scholar
Na SW, Yu SH, Kim KH, Hwang EC, Jung SI, Kwon DD, et al. The prognosis of patients less than 40 years with bladder Cancer. J Cancer Res Ther. 2014;10:710–4.PubMedGoogle Scholar
di ME, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol. 2012;2012:429213.Google Scholar